These findings highlight pharmacological activation of the HDAC1/TAF9 pathway as an attractive approach to alleviate NAFLD and identify DSS as a new candidate for NAFLD therapy. The gene discussed is TAF9; the disease is metabolic dysfunction-associated steatotic liver disease.